News | September 23, 2009

Philips, Celsion Advance MR-Guided HIFU, Thermodox Therapy Development

September 23, 2009 - Royal Philips Electronics and Celsion Corp. reported on a joint research program to evaluate ThermoDox, Celsion’s heat-activated liposomal drug, in combination with magnetic resonance-guided high intensity focused ultrasound (MR-HIFU) as a combination therapy to non-invasively treat difficult cancers has successfully completed the feasibility stage. The program has now moved into pre-clinical development and will focus on the combined use of ThermoDox and Philips’ MR-HIFU system for the treatment of pancreatic cancer and cancer metastases in bone.

Philips’ MR-HIFU system has the potential to precisely and non-invasively target lesions with acoustic energy, creating sufficient heat to activate ThermoDox and preferentially release high concentrations of the chemotherapy drug doxorubicin. This Celsion-Philips combinational treatment approach may change the paradigm for addressing a broad range of cancers.

Prominent experts in the field of MR-HIFU cancer treatment, including Dr. Bradford Wood of the National Institutes of Health Clinical Center, Dr. Chrit Moonen of the CNRS/University Victor Segalen Bordeaux and Dr. Kullervo Hynynen of Sunnybrook Health Sciences Centre, are participating in the Celsion-Philips research program. Under the leadership of Dr. Wood, these researchers will be conducting pre-clinical studies to assess doxorubicin drug delivery and to optimize MR-HIFU performance in this application. An Investigational New Drug (IND) submission is planned for early 2010, following successful completion of the pre-clinical studies.

The companies’ joint research is focused on the treatment of pancreatic cancer and cancer metastases in bone.

Pancreatic cancer is an aggressive cancer with an extremely high mortality rate. There are 37,000 annual incidences in the U.S, which ranks pancreatic cancer as the fourth leading cause of cancer deaths. Curative surgical resection (also known as the ‘Whipple’ procedure) is indicated in fewer than 20 percent of patients, while chemotherapeutic approaches provide modest, if any, patient survival benefit. These factors illustrate the high unmet need for better treatments and the potential significance of MR-HIFU’s mediated, targeted delivery of doxorubicin.

For bone metastases, ThermoDox combined with MR-HIFU will be investigated both for tumor control as well as for palliative pain treatment. Cancer progresses to bone metastases in a majority of patients with late-stage breast, prostate or lung cancer, with estimates of between 300,000 – 500,000 cases annually in the U.S. Patients typically experience excruciating and unrelenting pain, often treated with opiate drugs and NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) with modest benefit. External beam radiation therapy has been used for tumor control, but does not provide significant pain relief for many patients.

Related Content

Technology | Ultrasound Imaging | August 18, 2017
August 18, 2017 — SuperSonic Imagine recently introduced the newest version of its premium...
Pentax Medical Launches New Slim Linear Ultrasound Endoscope
Technology | Endoscopes | August 17, 2017
Pentax Medical Co. announced the U.S. launch of the Slim Linear Ultrasound Endoscope (EG-3270UK), the company's newest...
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Carestream Launches MR Brain Perfusion and Diffusion Modules for Vue PACS
Technology | Advanced Visualization | August 16, 2017
Carestream Health recently introduced new MR (magnetic resonance) Brain Perfusion and MR Brain Diffusion modules that...
ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Clarius Wireless Ultrasound Scanners Now Available With Advanced Features
News | Ultrasound Imaging | August 09, 2017
Clarius Mobile Health has released advanced features and options for its wireless handheld ultrasound scanner for...
MRI Reveals Striking Brain Differences in People with Genetic Autism

Example images for a control participant , a deletion carrier, and a duplication carrier. In the sagittal image of the deletion carrier, the thick corpus callosum, dens and craniocervical abnormality, and cerebellar ectopia are shown. For the duplication carrier, the sagittal image shows the thin corpus callosum and the axial image shows the increased ventricle size and decreased white matter volume. Image courtesy of the Radiological Society of North America (RSNA).

News | Neuro Imaging | August 09, 2017
August 9, 2017 — In the first major study of its kind, researchers using magnetic...
Oregon Tech Partners with Mindray for High-Tech Ultrasound Education
News | Ultrasound Imaging | August 04, 2017
To better prepare its ultrasound students to compete and thrive in the evolving healthcare environment, Oregon...
Overlay Init